Many prostate cancer cases present in the clinic with early-stage disease, and many will never progress to aggressive cancer. It is not currently possible to distinguish which patients require aggressive treatment and which do not. Providing clinicians with the tools to predict which patients are at risk of progressing in their disease would permit more aggressive decision making, ensuring that patients at high risk are treated aggressively, and those at low risk are protected from unneeded procedures. We have conducted a rigorous interrogation of existing patient data using computer based techniques and have isolated potential markers that are indicative of disease progression. This project will test these markers in a laboratory setting to determine the role in disease progression and will optimize a ‘predictive signature’ that can be tested in the clinic with patient populations. Improving the tools available for clinicians to guide treatment decisions will radically improve overall survival and quality of life for prostate cancer patients.